Keith Marschke, Ph.D.
About Keith Marschke, Ph.D.
Keith Marschke at Ligand Pharmaceuticals
Keith Marschke, Ph.D., serves as the Senior Vice President of Biology and Scientific Affairs at Ligand Pharmaceuticals. He joined the company in 1994 and has been instrumental in guiding numerous successful discovery and development programs. His leadership extends across several significant projects, including the Thrombopoietin (TPO) Receptor Agonist, Selective Androgen Receptor Modulator (SARM), Glucagon Receptor Antagonist (GRA), and Captisol-enabled Iohexol programs. Currently, Dr. Marschke leads clinical and scientific due diligence on asset purchase (royalties) and project finance investments.
Keith Marschke's Education and Expertise
Keith Marschke holds a Ph.D. in molecular and cellular pathobiology from the Bowman Gray School of Medicine at Wake Forest University. He also earned a Bachelor of Science in Biology from Oklahoma Baptist University. Before joining Ligand, Dr. Marschke completed a postdoctoral research position at the Laboratories for Reproductive Biology at the University of North Carolina, Chapel Hill. His extensive educational background and postdoctoral experience contribute to his expertise in molecular and cellular biology.
Keith Marschke's Leadership Roles in Drug Discovery
During his tenure at Ligand Pharmaceuticals, Keith Marschke has held leadership roles in several innovative discovery and development programs. Some of the key projects he has overseen include the Thrombopoietin (TPO) Receptor Agonist, Selective Androgen Receptor Modulator (SARM), Glucagon Receptor Antagonist (GRA), and Captisol-enabled Iohexol programs. His contributions have been pivotal to the success of these initiatives, impacting both internal advancements and collaborative efforts with partners.
Keith Marschke's Contributions to Publications and Patents
Keith Marschke has authored and contributed to numerous publications and patents reflecting his research and development work at Ligand Pharmaceuticals. His academic contributions support the scientific community and demonstrate his ongoing commitment to advancing molecular and cellular biology. These publications and patents are valuable assets to the industry, providing insights and innovations pivotal to drug discovery and development.